 Anchiano Therapeutics Ltd. ANCN Anchiano or the Company, a pivotal-stage biopharmaceutical company focused on the discovery and development of targeted therapies to treat cancer, today announced Stephen Hoffman, M.D., Ph.D. is stepping down from the Board of Directors effective immediately. Steve led the company through the initiation of its pivotal clinical trial Codex, to its public offering and Nasdaq listing, and the recent acquisition of its RAS-inhibitor program, said Frank Haluska M.D., Ph.D., President and Chief Executive Officer of Anchiano. 